Daiichi Sankyo Company, Limited
DSNKY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.74B
Close$
$24.17
38.6% upside
Current Fair Value
38.6% upsideUndervalued by 38.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $31.74 Billion |
|---|---|
| Enterprise Value | $-29,044,281,560.00 |
| Annual dividend | $0.49 |
| Dividend yield | 3.23% |
| Earnings per Share | $148.6 |
| Beta | 0.14 |
| Outstanding Shares | 1,819,826,000 |
Return
| Return on Equity | 14.61% |
|---|---|
| Return on Assets | 6.04% |
| Return on Invested Capital | 7.02% |
Valuation & Multiples
| P/E Ratio | 17.99 |
|---|---|
| PEG | -96.36 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | 2.19 |
| Enterprise Value to EBIT | 21.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$0.21
Consensus analyst estimateRevenue Estimate
$3.58 B
Consensus analyst estimateNext Earnings Call
Expected Date
January 29, 2027
EPS Estimate
$0.28
Consensus analyst estimateRevenue Estimate
$3.76 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Daiichi Sankyo Company, Limited
20,171 employees
CEO: Hiroyuki Okuzawa
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensi...